ADC One-stop Solution: Discovery, Development and Manufacturing
Dr. Derek Chen
Sr. Director, Biologics Discovery Dept. ProBio
Dr. Chen Li is the Sr. Director of Biologics Discovery Department of ProBio. After obtaining his doctorate in immunology from the University of Massachusetts School of medicine, he joined GenScript in 2015 and has been responsible for antibody drug discovery platform for the past seven years. He has more than 200 project experience in antibody drug discovery and Engineering innovation optimization, as well as three patents related to biopharmaceutical discovery.
Dr. Ying Li
Director of Downstream Process Development, ProBio
Dr. Ying Li is the Director of downstream process development at ProBio. She leads the CMC purification process development and provides technical leadership in new technology platform development. She joined ProBio in 2022, bringing over 10 years of biotechnology experience spanning multidisciplinary areas. Prior to joining ProBio, Dr. Li was an R&D Manager in Merck KGaA from 2017-2022, led the development of viral vector manufacturing platform and BioContinuum platform. Dr. Li obtained her B.S & Ph.D in Chemical Engineering from National University of Singapore and the Pennsylvania State University respectively. She is a frequent speaker at ACS and AIChE and has authored 8 publications in top tier bioprocessing journals.
Time
Topic
14:00-15:30
Accelerated ADC Development via Integrated Antibody Discovery Platform
Dr. Li Chen, Sr. Director of Biologics Discovery Dept., ProBio
Antibody-drug conjugates, also known as ADC, is a combination of traditional chemotherapy and targeted biological molecule. Recent clinical development brings lots of attention to this particular therapy in oncology filed. In this webinar, we will briefly go over the history and trending of ADC construct, followed by detail discussion of the tools and strategies for antibody discovery, as well as pharmacology assessment of antibody-drug conjugate.
14:00-15:30
Development and Manufacturing Strategies for Antibody-drug Conjugates
Dr. Ying Li, Director of Downstream Process Development, ProBio
Antibody-drug conjugates (ADCs) are a novel class of drugs that combine the potency of small molecule drugs with the targeting capabilities of antibodies. ADCs can be inherently complex and heterogeneous which present significant challenges for the process development and large-scale manufacturing. This talk focuses on the strategies to address common challenges encountered in ADC CMC. Case studies will be presented to highlight how to optimize and ensure a robust manufacturing process for ADCs.